Brokers Set Expectations for DYAI FY2024 Earnings

Dyadic International, Inc. (NASDAQ:DYAI) – Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Dyadic International in a report released on Wednesday, November 13th. HC Wainwright analyst V. Bernardino expects that the biotechnology company will post earnings of ($0.15) per share for the year. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Dyadic International’s Q4 2024 earnings at ($0.01) EPS and FY2025 earnings at ($0.06) EPS.

Dyadic International Price Performance

Shares of NASDAQ:DYAI opened at $1.22 on Monday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. The business’s fifty day moving average price is $1.12 and its two-hundred day moving average price is $1.41. The stock has a market cap of $36.10 million, a PE ratio of -5.30 and a beta of 0.72. Dyadic International has a one year low of $0.93 and a one year high of $2.67.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The company had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. During the same quarter in the previous year, the business posted ($0.06) earnings per share.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. grew its position in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 868,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the period. Chapin Davis Inc. owned 2.97% of Dyadic International worth $903,000 at the end of the most recent quarter. 27.95% of the stock is currently owned by institutional investors.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.